Home › Research › Treatments
A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD
Hovakimyan A, Madoyan H, Najarzadeh Z, Chilingaryan G, Petrushina I, Mamikonyan G, Lebedeva E, Zaitsev A et al.. Molecular neurodegeneration, 2026-07-22
Topic: Amyloid, tau and blood-test diagnosis
However, all Aβ vaccines tested so far in people with disease have faced significant challenges, primarily due to inadequate immunogenicity and insufficient antibody titers required to clear, reduce, or slow amyloid pathology. Results AV-1959R was safe and well-tolerated, with no serious adverse events or ARIA observed.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hovakimyan, A., Madoyan, H., Najarzadeh, Z., Chilingaryan, G., Petrushina, I., Mamikonyan, G., et al. (2026). A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD. Molecular neurodegeneration. https://doi.org/10.1186/s13024-026-00980-y
Vancouver
Hovakimyan A, Madoyan H, Najarzadeh Z, Chilingaryan G, Petrushina I, Mamikonyan G, et al. A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD. Molecular neurodegeneration. 2026. doi:10.1186/s13024-026-00980-y. PMID: 43000408.
BibTeX
@article{hovakimyan2026-43000408,
author = {Hovakimyan, A. and Madoyan, H. and Najarzadeh, Z. and Chilingaryan, G. and Petrushina, I. and Mamikonyan, G. and Lebedeva, E. and Zaitsev, A. and others},
title = {{A randomized, placebo-controlled, double blind Phase 1 trial of the Aβ vaccine, AV-1959R, in non-cognitively impaired participants: prelude for secondary preventive therapy in preclinical AD}},
journal = {Molecular neurodegeneration},
year = {2026},
doi = {10.1186/s13024-026-00980-y},
pmid = {43000408},
url = {https://doi.org/10.1186/s13024-026-00980-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, all Aβ vaccines tested so far in people with disease have faced significant challenges, primarily due to inadequate immunogenicity and insufficient antibody titers required to clear, reduce, or slow amyloid pathology.
- Results AV-1959R was safe and well-tolerated, with no serious adverse events or ARIA observed.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthHigh
How this study scored 81/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 47 of the 58 points we could judge it on, which is 81 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 43000408) |
| Free to read | 2 / 2 | Free to read |
| Points | 47 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 47 of the 58 points we could judge it on is 81 out of 100. |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “vaccine”
4 studies in the library carry the topic tag “vaccine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.